Numerous Growth Factors Can Influence in Vitro Megakaryocytopoiesis

RONALD HOFFMAN, M.D., ROBERT BRIDDELL, B.S., AND EDMOND BRUNO, M.S.

Department of Medicine, Division of Hematology/Oncology, Indiana University
School of Medicine, Indianapolis, Indiana

Received April 25, 1990

At least two classes of human megakaryocyte progenitor cells have been identified: the burst-forming unit megakaryocyte (BFU-MK) and the colony-forming unit megakaryocyte (CFU-MK). The BFU-MK is the most primitive progenitor cell committed to the megakaryocytic lineage. The CFU-MK appears to be a more differentiated megakaryocyte progenitor cell and is thought to be ultimately a descendant of the BFU-MK. A number of recombinant cytokines have recently been shown to be able to promote megakaryocyte colony formation in vitro. Recombinant GM-CSF and IL-3, in particular, have the ability to promote both CFU-MK- and BFU-MK-derived colony stimulatory formation. The activities of these two cytokines on in vitro megakaryocytopoiesis are also additive. Recent results of clinical trials in both primates and humans, in which these glycoproteins were administered in vivo, suggest that these cytokines, both alone and in combination, can enhance in vivo thrombopoiesis and therefore may be potentially useful in the treatment of thrombocytopenic disorders.

BACKGROUND

While the factors that control mammalian platelet production have now been studied for several decades, the mechanisms that control this process remain poorly defined. Although a number of investigators have clearly shown that the plasma of thrombocytopenic animals is capable of stimulating thrombopoiesis, the exact identity of the growth factors responsible for this activity has eluded the pursuit of a large number of research groups [1–3]. During the past decade, advances in protein purification and gene cloning have been applied to the isolation and characterization of hematopoietic growth factors. Recently, these new tools have been applied to the study of megakaryocytopoiesis, resulting in important new insights [1–4].

These investigations have been facilitated by the development of a variety of semisolid assay systems, utilized to detect megakaryocyte progenitor cells [5–15]. In vitro, these progenitor cells possess the ability to form colonies composed exclusively of megakaryocytic elements. The presence of a hierarchy of megakaryocyte progenitor cells is well established. This hierarchy has been defined by both the time of appearance and the cellular composition of colonies derived from such progenitors [16–19]. At

Abbreviations: Anti-GM-CSF Antisera: anti-granulocyte-macrophage colony-stimulating factor antisera Anti-IL-1α Antisera: anti-interleukin 1α antisera Anti-IL-6 Antisera: anti-interleukin 6 antisera BFU-MK: burst forming unit—megakaryocyte CFU-MK: colony-forming unit—megakaryocyte G-CSF: granulocyte colony-stimulating factor GM-CSF: granulocyte-macrophage colony-stimulating factor IL-1α: interleukin 1α IL-3: interleukin 3 IL-6: interleukin 6 MK-CSA: megakaryocyte colony-stimulating activity MK-CSF: megakaryocyte colony-stimulating factor NALDT−: non-adherent low density T-cell depleted

Supported in part by grant CA-34841 from the National Cancer Institute

Copyright © 1990 by The Yale Journal of Biology and Medicine, Inc.

All rights of reproduction in any form reserved.
present, at least two classes of megakaryocyte progenitor cells have been identified: the burst-forming unit megakaryocyte (BFU-MK) and the colony-forming unit megakaryocyte (CFU-MK)\[16,18,19\]. The BFU-MK is the most primitive progenitor cell committed to the megakaryocyte lineage \[16,18,19\]. The CFU-MK appears to be a more differentiated megakaryocyte progenitor cell and is thought to be ultimately a descendant of the BFU-MK. The assays developed to detect these progenitor cells are dependent upon their ability to form megakaryocyte colonies \textit{in vitro} in response to the addition of cytokines to semisolid media. The characteristics that allow one to differentiate between the CFU-MK and BFU-MK present in normal human marrow are listed in Table 1 \[18,19\].

A number of complex biological processes occur as the megakaryocyte progenitor cell differentiates and proceeds toward the ultimate production of mature platelets (Table 2). The megakaryocyte, a large but relatively rare cell present in human marrow, is unique because of its ability to undergo nuclear endoreplication while acquiring multiples of the normal amount of nuclear DNA. In this report we will discuss exclusively the regulatory factors that control megakaryocyte progenitor cell proliferation. It should be emphasized that while the processes of megakaryocyte maturation and endoreplication are also probably controlled by a variety of cytokines, this subject is beyond the scope of this discussion \[1-3\]. A number of groups have shown that the process of platelet production is regulated by one or more factors that influence different cellular steps along the schema of megakaryocyte development \[20-22\]. Williams et al. first suggested a two-factor requirement for megakaryocytopenesis, whereby a megakaryocyte colony-stimulating factor (MK-CSF) selectively promotes megakaryocyte colony formation while an additional factor, megakaryocyte potentiator factor, influences megakaryocyte maturation \[22\]. MK-CSF is defined as a unique lineage-specific cytokine which selectively promotes megakaryocyte colony formation \textit{in vitro}. The hypothesis that megakaryocytopenesis is regulated by distinct factors acting at different levels of cellular development has provided a framework for investigation of the cytokine regulation of megakaryocytopenesis.

| Characteristics of Human Megakaryocyte Progenitor Cells | BFU-MK | CFU-MK |
|----------------------------------------------------------|--------|--------|
| Time required for colonies to appear \textit{in vitro} | 21 days | 12 days |
| Cells/colony | 108.6 ± 4.4 | 11.6 ± 1.2 |
| Foci/colony | 2.3 ± 0.4 | 1.2 ± 0.1 |
| Elutriation profile | 12–14 ml/minute | 18–20 ml/minute |
| Phenotype | CD34+DR− | CD34+DR+ |
| Sensitivity to 5 Fluorouracil | Resistant | Sensitive |

| Events Occurring During Megakaryocytopenesis That Are Possibly Regulated by Humoral Factors |
|------------------------------------------------------------------------------------------|
| 1. Progenitor cell proliferation (BFU-MK, CFU-MK)                                        |
| 2. Megakaryocyte polyploidization                                                        |
| 3. Cytoplasmic maturation (membrane and organelle development) of megakaryocytes         |
| 4. Platelet release from megakaryocytes                                                   |
MEGAKARYOCYTE COLONY-STIMULATING FACTORS IN PLASMA

Urine, serum, and plasma obtained from patients with hypomegakaryocytic thrombocytopenia have been shown to be capable of promoting the formation of megakaryocytic colonies in vitro [23–29]. This megakaryocyte colony-stimulating activity (MK-CSA) is defined as the ability of conditioned media, plasma, serum, and purified or recombinant cytokines to promote megakaryocyte colony formation in semisolid media. It is unknown whether this MK-CSA is due to the presence of a single unique MK-CSF or a combination of several cytokines with MK-CSA. Data have been provided by several laboratories suggesting that the elaboration of MK-CSA in human plasma or serum is not directly related to platelet numbers but rather inversely related to megakaryocyte mass [23,24]. The elaboration of MK-CSA has been observed in a variety of clinical disorders, including selective amegakaryocytic thrombocytopenia, aplastic anemia, and marrow hypocellularity following cytotoxic chemotherapy or chemoradiotherapy in preparation for allogeneic marrow transplantation [23–29]. Miura et al. have developed a small animal model that provides an opportunity to define the relationship between platelet numbers and detectability of MK-CSA [24]. These investigators compared assayable MK-CSA in plasma of severely thrombocytopenic rats following irradiation to that detected in similarly irradiated animals who received platelet transfusions in order to maintain normal platelet numbers [24]. Assayable MK-CSA was equally elevated in each of these experimental groups as compared with animals not irradiated [24]. This work is in agreement with the hypothesis that MK-CSA elaboration occurs independently of platelet numbers.

The cytokines responsible for plasma MK-CSA in hypomegakaryocytic individuals must be identified in order to understand the contribution of various growth factors to CFU-MK regulation in vivo. The biochemical purification of each of these cytokines has recently been pursued by a number of different laboratories with limited success [27,30,31]. A number of sources of MK-CSA, including aplastic anemia urine, selective amegakaryocytic thrombocytopenia plasma, or thrombocytopenic plasma obtained following the administration of sublethal irradiation to dogs have each been used as starting materials for these purification procedures [23–29].

A polyclonal rabbit antiserum that neutralizes MK-CSA present in human plasma has been developed [32]. This antiserum did not neutralize the MK-CSA of interleukin 3 (IL-3) or granulocyte-macrophage colony-stimulating factor (GM-CSF) but did neutralize MK-CSA in a protein fraction partially purified from human plasma [32]. In addition, Mazur et al. recently reported that IL-3 and granulocyte-macrophage (GM)-CSF neutralizing antibodies do not diminish the MK-CSA present in plasma obtained from either thrombocytopenic dogs or humans [33]. These data collectively indicate the presence of an additional cytokine(s) apart from GM-CSF or IL-3 in human plasma exhibiting MK-CSA.

RECOMBINANT CYTOKINES WITH MEGAKARYOCYTE COLONY-STIMULATING ACTIVITY

Determination of the range of activities of the purified and recombinant cytokines already available have indicated that these cytokines can affect both in vitro and in vivo megakaryocytopoiesis. Some of these cytokines actually have MK-CSA, while others act in synergy with other factors to affect CFU-MK proliferation.

Data generated in a large number of laboratories are in agreement that recombinant
GM-CSF and IL-3 both individually have MK-CSA in addition to their ability to affect a number of other hematopoietic lineages [14,16,34–42]. In addition, the effects of GM-CSF and IL-3 are additive in that colony formation by a combination of these two growth factors approximates the sum of colony formation by each growth factor alone [14,35,42]. GM-CSF and IL-3 have also been shown to enhance BFU-MK-derived colony formation [19]. These actions on the BFU-MK are also additive. These cytokines not only increase colony formation, but also increase the number of cells comprising individual CFU-MK-derived colonies [14]. In addition, Briddell and Hoffman have shown that IL-1α augments the ability of IL-3 to promote BFU-MK-derived colony formation [19]. Although IL-1α by itself had no colony-stimulating activity, its synergistic effect occurred in a dose-related fashion [19]. These observations are in no way subtle in that optimal concentrations of both IL-1α and IL-3 promote similar numbers of BFU-MK-derived colonies, as do combinations of optimal concentrations of GM-CSF and IL-3 (Table 3) [19].

Recently, continuous infusions of human IL-3 in a primate, the cynomolgus macaque, have been reported to result in profound increases in mean platelet counts [43,44]. Administration of recombinant GM-CSF to primates also has resulted in some modest, albeit inconsistent, effects on platelet numbers [45]. Krumwied and Seiler have further explored the *in vivo* action of these cytokines by administering them in sequence [43,44]. Primates were first injected with IL-3 and then subsequently with GM-CSF [43,44]. Such priming with IL-3 followed by GM-CSF administration resulted in a dose-dependent significant increase in platelet numbers, even though IL-3 and GM-CSF alone, at the doses administered, had no significant influence on platelet numbers [44]. Most exciting of all, infusions of IL-3 to patients with a variety of hematological disorders and bone marrow failure states have resulted in a sixfold increase in platelet numbers in five out of eight evaluable patients [46]. This increase in platelet numbers resulted in increased marrow cellularity and appearance of greater numbers of marrow megakaryocytes [46]. These preliminary findings suggest that IL-3 might be a clinically useful pharmacological agent for the treatment of thrombocytopenic disorders.

Another recombinant cytokine, IL-6, has recently been shown to have profound effects on thrombopoiesis. IL-6 was originally characterized as a T-cell-derived factor that promoted the terminal maturation of activated B cells to immunoglobulin-

### Table 3

The Effect of Cytokine Combinations on BFU-MK-Derived Colony Formation

| Cytokine(s)                  | BFU-MK-Derived Colonies/5 × 10^3 CD34+DR− Cells Plated |
|-----------------------------|--------------------------------------------------------|
| None                        | 0.0 ± 0.0*                                             |
| GM-CSF 200.0 pg/ml          | 2.6 ± 0.4                                              |
| IL-1α 500.0 pg/ml           | 0.0 ± 0.0                                              |
| IL-3 1.0 ng/ml              | 5.8 ± 0.4                                              |
| GM-CSF + IL-1α              | 2.2 ± 0.6                                              |
| GM-CSF + IL-3               | 10.0 ± 1.8                                             |
| IL-1α + IL-3                | 9.4 ± 0.6                                              |

*Each point represents the mean ± the standard error of the mean of pooled data obtained from experiments performed in duplicate on at least four separate occasions.

GM-CSF and IL-3 both individually have MK-CSA in addition to their ability to affect a number of other hematopoietic lineages [14,16,34–42]. In addition, the effects of GM-CSF and IL-3 are additive in that colony formation by a combination of these two growth factors approximates the sum of colony formation by each growth factor alone [14,35,42]. GM-CSF and IL-3 have also been shown to enhance BFU-MK-derived colony formation [19]. These actions on the BFU-MK are also additive. These cytokines not only increase colony formation, but also increase the number of cells comprising individual CFU-MK-derived colonies [14]. In addition, Briddell and Hoffman have shown that IL-1α augments the ability of IL-3 to promote BFU-MK-derived colony formation [19]. Although IL-1α by itself had no colony-stimulating activity, its synergistic effect occurred in a dose-related fashion [19]. These observations are in no way subtle in that optimal concentrations of both IL-1α and IL-3 promote similar numbers of BFU-MK-derived colonies, as do combinations of optimal concentrations of GM-CSF and IL-3 (Table 3) [19].

Recently, continuous infusions of human IL-3 in a primate, the cynomolgus macaque, have been reported to result in profound increases in mean platelet counts [43,44]. Administration of recombinant GM-CSF to primates also has resulted in some modest, albeit inconsistent, effects on platelet numbers [45]. Krumwied and Seiler have further explored the *in vivo* action of these cytokines by administering them in sequence [43,44]. Primates were first injected with IL-3 and then subsequently with GM-CSF [43,44]. Such priming with IL-3 followed by GM-CSF administration resulted in a dose-dependent significant increase in platelet numbers, even though IL-3 and GM-CSF alone, at the doses administered, had no significant influence on platelet numbers [44]. Most exciting of all, infusions of IL-3 to patients with a variety of hematological disorders and bone marrow failure states have resulted in a sixfold increase in platelet numbers in five out of eight evaluable patients [46]. This increase in platelet numbers resulted in increased marrow cellularity and appearance of greater numbers of marrow megakaryocytes [46]. These preliminary findings suggest that IL-3 might be a clinically useful pharmacological agent for the treatment of thrombocytopenic disorders.

Another recombinant cytokine, IL-6, has recently been shown to have profound effects on thrombopoiesis. IL-6 was originally characterized as a T-cell-derived factor that promoted the terminal maturation of activated B cells to immunoglobulin-
producing cells [47]. This cytokine has been shown to be identical to B$_2$ interferon, 26 kd protein, and hybridoma growth factor [47]. Recently Ishibashi et al. have shown that in vivo administration of IL-6 produces an increase in peripheral platelet numbers while promoting megakaryocyte maturation and ploidy in vitro [48,49]. Hill et al. have also demonstrated a dose-response relationship between the amount of IL-6 administered and the level of increased platelet numbers detected in mice [50]. In addition, this group has shown that both the number of detectable murine splenic and marrow megakaryocyte colony-forming cells were increased in mice that had received IL-6 [50]. Ziedler et al. demonstrated that IL-6 administered to seven cynomolgus monkeys resulted in a 2–3.5-fold increase in the number of platelets [51]. Interestingly, no synergistic effects were observed in the peripheral blood of these animals when IL-6 was combined simultaneously with G-CSF, GM-CSF, or IL-3 [51].

Some question has arisen concerning the mechanism by which IL-6 affects megakaryocyte colony formation. Several investigators have reported that IL-6 alone has no MK-CSA [51–55]. Koike and co-workers have further suggested that IL-6 requires a factor or factors present in serum in order to promote megakaryocyte colony formation [56]. Other groups have, however, reported that IL-6 can act independently on non-adherent low-density T-cell-depleted bone marrow subpopulations (NALDT–) to promote megakaryocyte colony growth [57,58]. In addition, Lotem et al. have presented data to indicate that IL-6 plays an even more critical role in the regulation of the CFU-MK [59]. They have suggested that the induction of megakaryocyte colony formation by IL-3 is actually due to the endogenous production of IL-6 by bone marrow accessory cells [59].

Our group has shown that the addition of both human IL-1α and IL-6 to the NALDT– cell population resulted in the stimulation of CFU-MK-derived colony formation, while neither IL-1α or IL-6 alone stimulated megakaryocyte colony growth [60]. A similar synergistic effect of IL-1α and IL-6 on hematopoiesis affecting other cell lineages has been previously reported by several groups [61–64]. In addition, our studies indicate that the MK-CSA of IL-6 on low-density bone marrow cells can be significantly inhibited by the addition of anti-IL-1α polyclonal neutralizing antisera [60]. Similar additions of anti-GM-CSF antisera to low-density bone marrow cultures containing IL-6 had no effect on the MK-CSA of IL-6, indicating that the MK-CSA of IL-6 was not due to the secondary elaboration of GM-CSF [60]. Our findings therefore suggest that IL-6 cannot act alone on the CFU-MK from human bone marrow cells but rather requires the presence of IL-1α in order to promote megakaryocyte colony formation [60].

The hypothesis by Lotem et al. that IL-3 exerts its MK-CSA through the action of IL-6 is not supported by data generated in our laboratory [59]. The addition of anti-IL-6 antisera to cultures containing IL-3 had no significant effect on the MK-CSA of IL-3 [60]. Another discrepancy between our report and that of Lotem et al. concerns the appearance of megakaryocyte colonies in assays to which no exogenous cytokines are added. While Lotem et al. attributed such so-called baseline colony formation to the endogenous production of IL-6, our data failed to substantiate this conclusion [59,60]. The reasons for such discrepancies remain unknown.

The effect of the in vivo administration of IL-6 alone or in combination with other cytokines to animals or humans with disorders of thrombopoiesis remains unknown. The results of such studies are eagerly awaited.
CONCLUSION

Our understanding of the growth factors that control platelet production has greatly expanded over the last decade. The entry of these growth factors into clinical trial provides promise that in the future we will have to rely to a lesser degree upon platelet transfusion therapy for the treatment of patients with life-threatening thrombocytopenia. In addition, the availability of these cytokines may permit in vitro production of sufficient numbers of platelets that might be useful for transfusion therapy.

ACKNOWLEDGEMENT

We wish to thank Stephanie McGillem for her secretarial support during the preparation of this manuscript.

REFERENCES

1. Hill RJ, Levin J: Regulators of thrombopoiesis: Their biochemistry and physiology. Blood Cells 15:141–166, 1989
2. Mazur EM: Megakaryocytopenesis and platelet production: A review. Exp Hematol 15:340–350, 1987
3. McDonald TP: Thrombopoietin: Its biology, purification and characterization. Exp Hematol 16:201–205, 1988
4. Hoffman R: Regulation of megakaryocytopenesis. Blood 74:1196–1212, 1989
5. Nakeff A, Daniels-McQueen S: In vitro colony assay for a new class of megakaryocyte precursor: Colony-forming unit megakaryocyte (CFU-M). Proc Soc Exp Biol Med 151:587–590, 1976
6. Metcalf D, MacDonald HR, Odartchenko N, Sordat B: Growth of mouse megakaryocyte colonies in vitro. Proc Natl Acad Sci USA 72:1744–1748, 1975
7. McLeod DL, Shreve MM, Axelrad AA: Induction of megakaryocyte colonies with platelet formation in vitro. Nature 261:492–494, 1976
8. Vainchenker W, Bouguet J, Guichard J, Breton-Gorius J: Megakaryocyte colony formation from human bone marrow precursors. Blood 54:940–945, 1979
9. Mazur EM, Hoffman R, Chasis J, Marchesi S, Bruno E: Immunofluorescent identification of human megakaryocyte colonies using an antiplatelet glycoprotein antiserum. Blood 57:277–286, 1981
10. Messner HA, Jamal N, Izaguirre C: The growth of large megakaryocytic colonies from human bone marrow. J Cell Physiol (Supplement 1):45–51, 1982
11. Solberg LA Jr, Jamal N, Messner HA: Characterization of human megakaryocytic colony formation in human plasma. J Cell Physiol 124:67–74, 1985
12. Kimura H, Burstein SA, Torning SA, Powell JS, Harker LA, Fialkow PJ, Adamson JW: Human megakaryocytic progenitors (CFU-M) assaying in methylcellulose: Physical characteristics and requirements for growth. J Cell Physiol 118:87–96, 1984
13. Geissler DG, Konwalinka G, Peschel CH, Boyd J, Odavic R, Braunsteiner H: Clonal growth of human megakaryocyte progenitor cells in a microagar culture system: Simultaneous proliferation of megakaryocyte, granulocyte, erythroid progenitors (CFU-M, CFU-C, BFU-E) and T lymphocyte colonies (CFU-TL). Int J Cell Cloning 1:377–385, 1983
14. Bruno E, Briddell R, Hoffman R: Effect of recombinant and purified hematopoietic growth factors on human megakaryocyte colony formation. Exp Hematol 16:371–377, 1988
15. Sakaguchi M, Kawakita M, Matsushita J, Shibuya K, Koishihawa Y, Takatsuki K: Human erythropoietin stimulates murine megakaryocytopoiesis in serum free culture. Exp Hematol 15:1028–1034, 1987
16. Long MW, Gragowski LL, Effner CH, Boxer LA: Phorbol diesters stimulate the development of an early murine progenitor cell: The burst forming unit-megakaryocyte. J Clin Invest 76:431–438, 1985
17. Paulus JM, Prenant M, Deschamps JF, Amar MH: Polyploid megakaryocytes develop randomly from a multicompartmental system of committed progenitors. Proc Natl Acad Sci USA 79:4410–4414, 1982
18. Briddell RA, Brandt JE, Straneva JE, Sour EF, Hoffman R: Characterization of the human burst forming unit-megakaryocyte. Blood 74:145–151, 1989
19. Briddell RA, Hoffman R: Cytokine regulation of the human burst forming unit-megakaryocyte (BFU-MK). Blood, in press
20. Levin J, Levin FC, Metcalf D: The effects of acute thrombocytopenia on megakaryocyte-CFC and granulocyte-macrophage-CFC in mice: Studies of bone marrow and spleen. Blood 56:274–283, 1980
21. Burstein SA, Adamson JW, Erb SK, Harker LA: Megakaryocytopenia in the mouse: Response to varying platelet demand. J Cell Physiol 109:333–341, 1981

22. Williams N, Eger RR, Jackson HM, Nelson DJ: Two factor requirement for murine megakaryocyte colony formation. J Cell Physiol 110:101–104, 1982

23. Hoffman R, Mazur E, Bruno E, Floyd V: Assay of an activity in the serum of patients with disorders of thrombopoiesis that stimulates formation of megakaryocytic colonies. N Engl J Med 305:533–538, 1981

24. Miura M, Jackson CW, Steward SA: Increase in circulating megakaryocyte growth-promoting activity (Meg-GPA) following sublethal irradiation is not related to decreased platelets. Exp Hematol 16:139–144, 1988

25. Kawakita M, Enomoto K, Katayama N, Kishimoto S, Miyake T: Thrombopoiesis and megakaryocyte colony-stimulating factors in the urine of patients with idiopathic thrombocytopenic purpura. Br J Haematol 48:609–615, 1981

26. Kawakita M, Ogawa M, Goldwasser E, Miyake T: Characterization of human megakaryocyte colony-stimulating factor in the urinary extracts from patients with aplastic anemia and idiopathic thrombocytopenic purpura. Blood 61:556–560, 1983

27. Mazur EM, South K: Human megakaryocyte colony-stimulating factor in sera from aplastic dogs: Partial purification, characterization and determination of hematopoietic cell lineage specificity. Exp Hematol 13:1164–1172, 1985

28. Mazur EM, de Alarcon P, South K, Miceli L: Human serum megakaryocyte colony stimulating activity increases in response to intensive cytotoxic chemotherapy. Exp Hematol 12:624–628, 1984

29. Geissler K, Hinterberger W, Fisher M, Lechner K: Megakaryocyte-stimulating factors are highly increased in sera from patients after bone marrow transplantation (Abstract). Exp Hematol (Supplement 17) 13:97, 1985

30. Hoffman R, Yang HH, Bruno E, Stranava JE: Purification and partial characterization of a megakaryocyte colony stimulating factor from human plasma. J Clin Invest 75:1174–1182, 1985

31. Abe T, Fuher P, Bregman MD, Kuramoto A, Murphy MJ Jr: Factors regulating megakaryocytopenesis and platelet formation. In Molecular Biology of Hemopoiesis. Edited by M Tavassoli, ED Zanjani, JL Ascensao, NG Abraham, AS Levene. New York, Plenum, 1988, pp 183–190

32. Yang HH, Bruno E, Hoffman R: Studies of human megakaryocytopenesis using an anti-megakaryocyte colony stimulating factor antiserum. J Clin Invest 77:1873–1880, 1986

33. Mazur EM, Cohen JL, Newton J, Gesner TG, Mufson RA: Human serum megakaryocyte (MK) colony stimulating activity (Meg-CSA) is distinct from interleukin-3 (IL-3), granulocyte macrophage colony stimulating factor (GM-CSF) and phytohemagglutinin stimulated lymphocyte conditioned medium (PHA-LCM) (Abstract). Blood (Supplement 1) 72:331a, 1988

34. Quesenberry PJ, Ihle JN, McGrath HE: The effect of interleukin-3 and GM-CSF-2 on megakaryocyte and myeloid clonal colony formation. Blood 65:214–217, 1985

35. Robinson BE, McGrath HE, Quesenberry PJ: Recombinant murine granulocyte macrophage colony-stimulating factor has megakaryocyte colony-stimulating activity and augments megakaryocyte colony-stimulation by interleukin 3. J Clin Invest 79:1648–1652, 1987

36. Mazur EM, Cohen JL, Wong G, Clark SC: Modest stimulating effect of recombinant human GM-CSF on colony growth from peripheral blood human megakaryocyte progenitor cells. Exp Hematol 15:1128–1133, 1987

37. Kaushansky K, O'Hara PJ, Berkner K, Segal GM, Hagen FS, Adamson JW: Genomic cloning, characterization, and multilineage growth-promoting activity of human granulocyte-macrophage colony-stimulating factor. Proc Natl Acad Sci USA 83:3101–3105, 1986

38. Sieff CA, Niemeyer CM, Nathan DG, Ekern SC, Bieber FR, Yang YC, Wong G, Clark SC: Stimulation of human hematopoietic colony formation by recombinant gibbon multi-colony-stimulating factor or interleukin 3. J Clin Invest 80:818–823, 1987

39. Lopez AF, To LB, Yang YC, Gamble JR, Shannon MF, Burns GF, Dyson PG, Juttner CA, Clark S, Vadas MA: Stimulation of proliferation, differentiation, and function of human cells by primate interleukin 3. Proc Natl Acad Sci USA 84:2761–2765, 1987

40. Mizoguchi H, Fujwara Y, Sasaki R, Chiba H: The effect of interleukin 3 and erythropoietin on murine megakaryocyte colony formation. In Megakaryocyte Development and Function. Edited by RF Levine, N Williams, J Levin, BL Evatt. New York, Alan R Liss, 1986, pp 111–115

41. Teramura M, Katahira J, Hoshino S, Motoji T, Oshimi K, Mizoguchi H: Clonal growth of human megakaryocyte progenitors in serum free cultures: Effect of recombinant human interleukin 3. Exp Hematol 16:843–848, 1988
42. Messner HA, Yarnasaki K, Jamal N, Minden MM, Yang YC, Wong GG, Clark SC: Growth of human hemopoietic colonies in response to recombinant gibbon interleukin 3: Comparison with human recombinant granulocyte and granulocyte-macrophage colony-stimulating factor. Proc Natl Acad Sci USA 84:6765–6769, 1987

43. Krumweih D, Seiler FR: Changes of hematopoiesis in cynomolgus monkeys after application of human colony-stimulating factors (Abstract). Exp Hematol 16:551, 1988

44. Krumweih D, Seiler FR: In vivo effects of recombinant interleukin 3 alone or in various combinations with other cytokines as GM-CSF, G-CSF and Epo in normal cynomolgus monkeys (Abstract). J Cell Biochem 136 (Supplement):51, 1989

45. Donahue RE, Wang EA, Stone DK, Kamen R, Wong GG, Sehgal PK, Nathan DG, Clark SC: Stimulation of haematopoiesis in primates by continuous infusion of recombinant human GM-CSF. Nature 321:872–875, 1986

46. Ganser A, Lindemann A, Seipel G, Ottmann OG, Herrmann F, Schulz G, Mertelsmann R, Hoelzer D: Effect of recombinant interleukin-3 (rh IL-3) in patients with bone marrow failure (Abstract). Blood (Supplement 1) 74:50a, 1989

47. Wong GG, Clark SC: Multiple actions of interleukin 6 within a cytokine network. Immunol Today 9:137–139, 1988

48. Ishibashi T, Kimura H, Uchida T, Kariyone S, Friese P, Burstein SA: Human interleukin 6 is a direct promoter of maturation of megakaryocytes in vitro. Proc Natl Acad Sci USA 86:5953–5957, 1989

49. Ishibashi T, Kimura H, Shikama Y, Uchida T, Kariyone S, Hirano T, Kishimoto T, Takatsuki F, Akiyama Y: Interleukin 6 is a potent thrombopoietic factor in vivo in mice. Blood 74:1241–1244, 1989

50. Hill RJ, Warren MK, Levin J: Stimulation of thrombopoiesis in mice by human recombinant interleukin 6. J Clin Invest 85:1242–1247, 1990

51. Zeidler C, Souza L, Welte K: In vivo effects of interleukin 6 on hematopoiesis in primates (Abstract). Blood (Supplement 1) 74:154a, 1989

52. Bruno E, Hoffman R: Effect of interleukin 6 on in vitro human megakaryocytopoiesis: Its interaction with other cytokines. Exp Hematol 17:1038–1043, 1989

53. Teramura M, Katahira J, Hoshino S, Motoji T, Oshimi K, Mizoguchi H: Effect of recombinant growth factors on human megakaryocyte colony formation in serum-free cultures. Exp Hematol 17:1011–1016, 1989

54. Wong GG, Witek-Giannotti JS, Temple PA, Kriz R, Ferenz C, Hewick RM, Clark SC, Ikebuchi K, Ogawa M: Stimulation of murine hemopoietic colony formation by human IL-6. J Immunol 140:3040–3044, 1988

55. Ikebuchi K, Wong GG, Clark SC, Ihle JN, Hirai Y, Ogawa M: Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hematopoietic progenitors. Proc Natl Acad Sci USA 84:9035–9039, 1987

56. Koike K, Tatsutoshi N, Mineo T, Kobayashi T, Ishiguro A, Tsuji K, Naganuma K, Okano A, Akiyama Y, Akabane T: Synergism of BSF-2/interleukin 6 and interleukin 3 on development of multipotential hematopoietic progenitors in serum-free culture. J Exp Med 168:879–890, 1988

57. Robinson BE, McGrath HE, McNiece IK, Clark SC, Gillis S, Quesenberry PJ: Interleukin 6 (IL-6) stimulation of murine megakaryocyte colony formation (Abstract). Clin Res 37(2):549a, 1989

58. McGrath HE, Robinson BE, McNiece IK, Deacon DH, Clark S, Quesenberry PJ: Interleukin 6 and multifactor stimulation of murine megakaryocyte colony formation (Abstract). Blood (Supplement 1) 74:154a, 1989

59. Lotem J, Shabo Y, Sachs L: Regulation of megakaryocyte development by interleukin 6. Blood 74:1545–1551, 1989

60. Bruno E, Hoffman R: The effect of interleukin 6 on human megakaryocytopoiesis (Abstract). Exp Hematol 18:595, 1990

61. Caracciolo D, Clark SC, Rovera G: Human interleukin-6 supports granulocytic differentiation of hematopoietic progenitor cells and acts synergistically with GM-CSF. Blood 73:666–670, 1989

62. Renauld J-C, Vink A, Snick JV: Accessory signals in murine cytolytic T cell responses. Dual requirement for IL-1 and IL-6. J Immunol 143:1894–1898, 1989

63. Kunimoto DY, Nordan RP, Strober W: IL-6 is a potent cofactor of IL-1 in IgM synthesis and of IL-5 in IgA synthesis. J Immunol 143:2230–2235, 1989

64. Warren MK, Conroy LB, Rose JS: The role of interleukin 6 and interleukin 1 in megakaryocyte development. Exp Hematol 17:1095–1099, 1989